Biopharma Co. to Launch Two Clinical Trials This Year
  (5/14/22)
Success in either program, atopic dermatitis or asthma, "could lead to multiblockbuster sales," noted a ROTH Capital Partners report. More >

Japan Pharma Co. Invests $275 Million in U.S. Oncology Firm
Source: Streetwise Reports  (5/13/22)
Cullinan Oncology Inc. shares traded 23% higher yesterday after the company reported it entered into a strategic investment, development, and licensing agreement with Taiho Pharmaceutical Co. Ltd. of Japan for its CLN-081/TAS6417 for use in treatment of non-small cell lung cancer. More >

First Results From Biotech Co.'s Lymphoma Program Are Impressive
  (5/13/22)
This data will be presented at the 2022 annual meeting of the European Hematology Association on June 11th, noted a ROTH Capital Partners report. More >

Pfizer Offers $11.6B to Buy Biopharma Co.
Source: Streetwise Reports  (5/10/22)
Shares of Biohaven Pharmaceutical Holding Co. Ltd. traded almost 70% higher after the company reported it agreed to be acquired by Pfizer Inc. for $148.50 per share in cash plus future royalty opportunities. More >

Analyst Says Avivagen Is a Strong Buy
Source: Clive Maund  (5/5/22)
With Avivagen's breakthrough product relishing in its success, Analyst Clive Maund reviews if he believes it is now a formidable contender as a Buy. More >

Biopharma Co. Licenses Orphan Drug to UK Firm for $450M
Source: Streetwise Reports  (5/5/22)
Intercept Pharmaceuticals Inc. shares traded 20% higher after the company reported it entered into a $450 million licensing agreement with Advanz Pharma in markets outside of the U.S. for Ocaliva® for use in treatment of primary biliary cholangitis, a progressive and chronic autoimmune disease which affects the liver. More >

Pilot Launch of VLN Cigarettes in Progress
  (5/3/22)
These "very low nicotine" tobacco products will be an alternative for smokers when the FDA effects its imminent menthol cigarette ban, noted a ROTH Capital Partners report. More >

Biotech Co. Advances COVID-19 Vaccines Toward Approval
  (5/1/22)
They include booster vaccines for different age groups of children and an Omicron-targeting booster for adults, noted an H.C. Wainwright & Co. report. More >

Could a New Prescription Drug Treat This Common Ailment?
  (4/27/22)
The combination drug Halo-Lido is poised to be the first-of-its-kind prescription treatment approved by the U.S. Food and Drug Administration for this prevalent medical condition, noted a DawsonJames report. More >

Biopharma Co. Posts 32% YoY Gain in Proprietary Sales
Source: Streetwise Reports  (4/27/22)
Alkermes Plc. shares traded 12% higher after the Ireland-based company reported Q1/22 financial results and reiterated its FY/22 business outlook. More >

Biopharma Co. Posts Positive Data in Ph. 1 Cancer Trials
Source: Streetwise Reports  (4/25/22)
Nkarta Inc. shares traded over 120% higher after the company reported positive dosing data from two separate Phase 1 clinical trials evaluating the use of natural killer cell therapies to target r/r acute myeloid leukemia and myelodysplastic syndrome and r/r B cell malignancies. More >

FDA Grants RMAT Status for T-Cell Therapy for Six Viruses
Source: Streetwise Reports  (4/20/22)
Shares of AlloVir Inc. traded 18% higher after the firm reported that the U.S. FDA awarded Regenerative Medicine Advanced Therapy designation to its posoleucel for use in preventing life-threatening infections from six viruses in allogeneic hematopoietic cell transplant patients. More >

Senior Biotech Analyst's Top 3 Stocks
Source: Streetwise Reports  (4/19/22)
Streetwise Reports recently spoke to renowned biotech expert John Vandermosten (CFA) about three of his favorite healthcare companies that are addressing as-of-yet unmet market needs. More >

Biotech Co.'s Shares Quadruple on $250M Buyout Bid
Source: Streetwise Reports  (4/19/22)
Shares of Checkmate Pharmaceuticals Inc. traded 330% higher to a new 52-week high after the company reported it agreed to be acquired by Regeneron Pharmaceuticals Inc. for $10.50 per share in cash. More >

Life Sciences Co. Expected to Attract Partners, Big Pharma
  (4/19/22)
"We foresee continued execution on its developmental strategy," noted Argus Research on this development stage biotech company tackling neurodegenerative diseases. More >

Vaccine Maker Awarded Approval for COVID-19 Vaccine
Source: Streetwise Reports  (4/14/22)
Shares of Valneva SE traded 8.5% higher after the company reported that the U.K.'s MHRA has granted Conditional Marketing Authorization for its inactivated whole-virus COVID-19 vaccine candidate called VLA2001 for primary immunization in adults between 18 and 50 years old. More >

GSK Offers $1.9B for Cancer-Focused Pharma Co.
Source: Streetwise Reports  (4/13/22)
Shares of Sierra Oncology Inc. traded 38% higher after the company reported it agreed to be acquired by GlaxoSmithKline Plc. for $55 per share in cash. More >

Biopharma Firm Signs $452M License Deal for BMT Drug
Source: Streetwise Reports  (4/12/22)
Shares of Actinium Pharmaceuticals Inc. traded 24% higher after the company reported it entered into a licensing and supply agreement for its antibody radiation conjugate, Iomab-B, with Sweden's Immedica Pharma AB for sales in Europe, the Middle East and North Africa. More >

Novel Drug Reduces COVID-19 Deaths by 55% in Ph. 3 Trial
Source: Streetwise Reports  (4/11/22)
Shares of Veru Inc. traded 180% higher after company reported interim data from a Phase 3 clinical study of its COVID-19 drug candidate sabizabulin which was shown to reduce deaths in hospitalized patients by 55%. More >

Co. Uses Protein Modulation to Treat Cancer
Source: Streetwise Reports  (4/9/22)
Nurix Therapeutics Inc. shares traded 13% higher after the company reported Q1/22 financial results and released an outline for two poster presentations that will be submitted at the American Association for Cancer Research Annual Meeting this weekend. More >

FDA Approves Bipolar and Schizophrenia Drug
Source: Streetwise Reports  (4/6/22)
BioXcel Therapeutics Inc. reported that the U.S. FDA has approved its IGALMIâ„¢ (dexmedetomidine) Sublingual Film for use in acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. More >

Can We Make a Pill to End the Pandemic?
Source: Vision and Value  (4/4/22)
Vision and Value discusses the state of the virus and big pharma's race to slow the death rate as well as the spread of the pandemic — and what it means for investors. More >

Biopharma Co. Begins Dosing in Ph. 1 Solid Tumor Trial
Source: Streetwise Reports  (4/2/22)
NGM Biopharmaceuticals Inc. shares rose 14.75% after the company reported it dosed the first group of patients in its Phase 1/1b clinical trial of NGM831 for use in treating advanced solid tumors. More >

Chen's Top Picks for Q2 2022
Source: Streetwise Reports  (4/1/22)
Asset manager and contributing writer Chen Lin looks to the biotechnology and mining sectors for his top second quarter picks. More >

Biotech Co. Posts Notable PFS Gains in Ph. 3 Cancer Trial
Source: Streetwise Reports  (3/31/22)
Clovis Oncology Inc. shares traded 36% higher after the company reported that in the Phase 3 ATHENA-MONO clinical study its Rubraca® (Rucaparib) was shown to significantly improve progression-free survival in women diagnosed with ovarian cancer. More >